JP2020533016A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533016A5
JP2020533016A5 JP2020529100A JP2020529100A JP2020533016A5 JP 2020533016 A5 JP2020533016 A5 JP 2020533016A5 JP 2020529100 A JP2020529100 A JP 2020529100A JP 2020529100 A JP2020529100 A JP 2020529100A JP 2020533016 A5 JP2020533016 A5 JP 2020533016A5
Authority
JP
Japan
Prior art keywords
amino acid
antigen
acid sequence
seq
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020529100A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533016A (ja
JP7801095B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/044778 external-priority patent/WO2019028125A1/en
Publication of JP2020533016A publication Critical patent/JP2020533016A/ja
Publication of JP2020533016A5 publication Critical patent/JP2020533016A5/ja
Priority to JP2023105890A priority Critical patent/JP7685771B2/ja
Priority to JP2025072790A priority patent/JP2025111661A/ja
Application granted granted Critical
Publication of JP7801095B2 publication Critical patent/JP7801095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020529100A 2017-08-01 2018-08-01 二重特異性抗体およびその使用 Active JP7801095B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023105890A JP7685771B2 (ja) 2017-08-01 2023-06-28 二重特異性抗体およびその使用
JP2025072790A JP2025111661A (ja) 2017-08-01 2025-04-25 二重特異性抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762539970P 2017-08-01 2017-08-01
US62/539,970 2017-08-01
US201862654112P 2018-04-06 2018-04-06
US62/654,112 2018-04-06
PCT/US2018/044778 WO2019028125A1 (en) 2017-08-01 2018-08-01 Bispecific antibodies and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023105890A Division JP7685771B2 (ja) 2017-08-01 2023-06-28 二重特異性抗体およびその使用
JP2025072790A Division JP2025111661A (ja) 2017-08-01 2025-04-25 二重特異性抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2020533016A JP2020533016A (ja) 2020-11-19
JP2020533016A5 true JP2020533016A5 (enExample) 2021-09-09
JP7801095B2 JP7801095B2 (ja) 2026-01-16

Family

ID=65233048

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020529100A Active JP7801095B2 (ja) 2017-08-01 2018-08-01 二重特異性抗体およびその使用
JP2023105890A Active JP7685771B2 (ja) 2017-08-01 2023-06-28 二重特異性抗体およびその使用
JP2025072790A Pending JP2025111661A (ja) 2017-08-01 2025-04-25 二重特異性抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023105890A Active JP7685771B2 (ja) 2017-08-01 2023-06-28 二重特異性抗体およびその使用
JP2025072790A Pending JP2025111661A (ja) 2017-08-01 2025-04-25 二重特異性抗体およびその使用

Country Status (7)

Country Link
US (5) US12049517B2 (enExample)
EP (2) EP4088783A1 (enExample)
JP (3) JP7801095B2 (enExample)
KR (2) KR102794369B1 (enExample)
CN (3) CN113896797B (enExample)
ES (1) ES3023158T3 (enExample)
WO (1) WO2019028125A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113896797B (zh) * 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2020177717A1 (zh) * 2019-03-04 2020-09-10 上海一宸医药科技有限公司 新型双特异性结合分子及其药物偶联物
WO2020198683A1 (en) * 2019-03-28 2020-10-01 Ab Studio Inc. Heteromultimeric proteins and methods of use thereof
US11702474B2 (en) * 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
WO2022100694A1 (zh) * 2020-11-12 2022-05-19 迈威(上海)生物科技股份有限公司 抗体及其制备方法
CN112430271B (zh) * 2020-11-13 2021-09-03 武汉滨会生物科技股份有限公司 一种双特异性单链抗体及应用
US20250320309A1 (en) * 2021-11-25 2025-10-16 Shenghe (China) Biopharmaceutical Co., Ltd. Bispecific antigen binding protein
CN116143948A (zh) * 2023-02-14 2023-05-23 中国药科大学 一种以Jurkat为平台的靶向CD24和PD-L1双特异性嵌合抗原受体CAR及其应用
CN119855835A (zh) * 2023-06-13 2025-04-18 南京维立志博生物科技股份有限公司 基于共同轻链产生双特异性抗体的方法
WO2026011331A1 (zh) * 2024-07-10 2026-01-15 嘉和生物药业有限公司 一种稳定的双特异性抗体组合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
RU2004127458A (ru) 2002-02-14 2005-10-27 Иммуномедикс, Инк. (Us) Анти-cd20 антитела, их гибридные белки и способы их использования
AU2003295330A1 (en) 2002-09-16 2004-05-04 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
DE602004021095D1 (de) 2003-01-21 2009-06-25 Chugai Pharmaceutical Co Ltd Verfahren zum screening der leichten kette eines antikörpers
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
CA2603264C (en) 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
PT1976880T (pt) 2005-12-21 2016-09-28 Amgen Res Munich Gmbh Composições farmacêuticas com resistência a cea solúvel
EP2009101B1 (en) * 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
MX2008015771A (es) * 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
LT2975051T (lt) * 2009-06-26 2021-07-12 Regeneron Pharmaceuticals, Inc. Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
US9624298B2 (en) * 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
PT2794905T (pt) * 2011-12-20 2020-06-30 Medimmune Llc Polipéptidos modificados para estrutura de anticorpos bispecíficos
RU2014138474A (ru) 2012-02-24 2016-04-10 СтемСентРкс, Инк. Новые модуляторы и способы применения
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
KR102023401B1 (ko) * 2012-05-10 2019-11-04 바이오아트라, 엘엘씨 다중-특이적 모노클로날 항체
US20140154253A1 (en) 2012-07-13 2014-06-05 Zymeworks Inc. Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs
WO2014028560A2 (en) * 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
EA038367B1 (ru) 2013-05-20 2021-08-16 Дженентек, Инк. АНТИТЕЛА ПРОТИВ РЕЦЕПТОРА ТРАНСФЕРРИНА (TfR) И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ
CN105531374A (zh) * 2013-07-12 2016-04-27 酵活有限公司 双特异性cd3和cd19抗原结合构建体
RU2016115866A (ru) * 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
CA2925677A1 (en) 2013-12-20 2015-06-25 F. Hoffmann-La Roche Ag Bispecific her2 antibodies and methods of use
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
TWI754319B (zh) * 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
MX2017006016A (es) 2014-11-11 2017-06-19 Amunix Operating Inc Composiciones conjugadas de xten direccionadas y metodos para producir las mismas.
SG11201704283PA (en) * 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
CN110655582B (zh) 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
WO2016110576A1 (en) * 2015-01-08 2016-07-14 Genmab A/S Bispecific antibodies against cd3 and cd20
JP2018502859A (ja) 2015-01-09 2018-02-01 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 二重特異性抗体を用いた事前標的指向化による腫瘍の治療
US10464999B2 (en) * 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
AU2016293942B2 (en) * 2015-07-10 2022-06-16 Merus B.V. Human CD3 binding antibody
AU2016333517B2 (en) * 2015-10-02 2023-09-07 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
JP7058219B2 (ja) * 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
AU2016370821A1 (en) * 2015-12-18 2018-07-12 Biogen Ma Inc. Bispecific antibody platform
CN113896797B (zh) * 2017-08-01 2023-05-09 Ab工作室有限公司 双特异性抗体及其用途

Similar Documents

Publication Publication Date Title
JP2019527553A5 (enExample)
JP2025160458A5 (enExample)
TWI821474B (zh) Ｃｄ３抗體及其藥物用途
JP2023504016A5 (enExample)
JP2019532619A5 (enExample)
JP2024522360A5 (enExample)
JP2020536504A5 (enExample)
JP2018522888A5 (enExample)
JP2018516853A5 (enExample)
JP2018523493A5 (enExample)
JP2018532766A5 (enExample)
JP2023551027A5 (enExample)
CA2583910A1 (en) Angiopoietin-2 specific binding agents
JP2013506428A5 (enExample)
JP2017504578A5 (enExample)
JP2021516051A5 (enExample)
JP2021520832A5 (enExample)
JP2020534830A5 (enExample)
JP2010502183A5 (enExample)
JP2021515798A5 (enExample)
JP2018505681A5 (enExample)
JP2021517152A5 (enExample)
RU2018102803A (ru) Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5
JP2023509390A5 (enExample)
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use